Culture Medium And Culturing Method For Anchorage-Dependent Cells, Cell Composition Including Stem Cells And/Or Differentiated Cells Derived From Stem Cells, And Production Method For Cell Composition
Kyowa Hakko Kirin Co. | Date: 2017-04-05
As a technique capable of culturing anchorage-dependent cells without using an anchorage, provided is a medium for anchorage-dependent cells, which comprises MFG-E8 (Milk fat globule-EGF factor 8) or a fragment of the protein. This medium can promote adhesion of anchorage-dependent cells in the absence of an anchorage, enables the survival and proliferation (colony formation) of the cells, and further, also enables the subsequent differentiation if the anchorage-dependent cells are stem cells.
E.R. Squibb & Sons L.L.C. and Kyowa Hakko Kirin Co. | Date: 2016-10-19
The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
Kyowa Hakko Kirin Co. | Date: 2016-11-03
There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.
Kyowa Hakko Kirin Co. | Date: 2017-05-03
The present invention provides a cationic lipid represented by the formula (I)^(1) and R^(2) each represents alkyl having 8 to 24 carbon atoms or the like; R^(3) represents a hydrogen atom, alkyl having 1 to 3 carbon atoms, the formula (A)^(4) and R^(5) each represents a hydrogen atom or the like, and n^(3) represents an integer from 2 to 6, or the formula (B)^(6) and R^(7) each represents a hydrogen atom or the like, and n^(4) represents an integer from 1 to 6; n^(1) represents an integer from 0 to 4; and n^(2) represents an integer from 1 to 4, provided that the case where n^(1) is 0 and n^(2) is 1 is excluded, and a composition which contains the cationic lipid and a nucleic acid, or the like.
Kyowa Hakko Kirin Co. | Date: 2016-12-16
Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required. The present invention provides an antibody variant composition, comprising amino acid residues of an Asn-X-Ser/Thr (X represents an amino acid residue other than Pro) sequence at positions other than positions 297 to 299 according to the EU index in an Fc region of a human IgG antibody, in which at least one amino acid substitution selected from an amino acid substitution of Asn to other amino acid residue, an amino acid substitution of X to Pro and an amino acid substitution of Ser/Thr to other amino acid residue is carried out, and a fragment of the antibody variant composition.
Kyowa Hakko Kirin Co. | Date: 2017-06-21
To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).
Pfizer and Kyowa Hakko Kirin Co. | Date: 2017-03-29
The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.
Kyowa Hakko Kirin Co. | Date: 2017-02-08
According to the present invention, anti-death receptor 3 (DR3) antagonistic IgG antibodies and antibody fragments thereof, wherein the antibodies and the antibody fragments thereof display a decreased agonistic activity or no agonistic activity for DR3 through their binding, an antibody compositions and an antibody fragment compositions comprising them, a nucleotide sequence encoding the antibody or the antibody fragment, a vector comprising the nucleotide sequences, an amino acid sequences of the antibodies or the antibody fragments, a method of producing the antibodies or the antibody fragments thereof, and a method of decreasing the agonistic potency of an antibody against DR3 through its binding, are provided.
Ultragenyx Pharmaceutical and Kyowa Hakko Kirin Co. | Date: 2017-04-12
The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
Kyowa Hakko Kirin Co. | Date: 2017-01-24
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A_(2A )receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinsons disease. The present invention further provides methods and compositions for treating Parkinsons disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A_(2A )receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinsons disease by co-administering at least one adenosine A_(2A )receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinsons disease by administering an adenosine A_(2A )receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.